Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Diabetes is a chronic disease that progresses over decades
#ObesityMedicine #MetabolicHealth #PrecisionMedicine #Endocrinology #GLP1 #Tirzepatide #Semaglutide #BariatricSurgery #ChronicDisease #HealthcareInnovation #LifestyleMedicine To view or add a comment, sign in OBESITY NEWS Recent press release by Novo Nordisk highlights interesting points CHRONIC DISEASE Obesity should be approached as a chronic, progressive, and multifactorial disease, not as a matter of willpower
--- Sources Neeland et al., Changes in lean body mass with GLP-1-based therapies and mitigation strategies , Diabetes, Obesity and Metabolism (2024): Jensterle et al., Rethinking Muscle Health Assessment in GLP-1-Based Therapies for Obesity: Beyond Lean Mass , DOM (2026): Wilding et al., STEP 1 body composition exploratory analysis: LEAN-PREP randomised controlled trial protocol (2025): Function and Lean Mass Preservation With Resistance Exercise During GLP-1RA Treatment, ClinicalTrials.gov: WHO Guidelines on Physical Activity and Sedentary Behaviour: Wegovy Singapore availability and prescription status:
Comprehensive healthcare provider reviews should occur at least every 3-6 months during maintenance, with monitoring of weight, metabolic markers, gastrointestinal tolerance, nutritional status, and safety parameters including kidney function and retinopathy screening for patients with diabetes
None of these compounds are approved by Health Canada for general therapeutic use they operate in various specific contexts
US$ 23.48
US$ 26.41
US$ 25.55
US$ 28.57
US$ 29.64
